Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 10/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 1.00 |
| ▸ | HTR3B | O95264 | 4/20 | 1.00 |
| ▸ | HTR3A | P46098 | 4/20 | 1.00 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 1.00 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.58 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pnu-282987 SCHEMBL6208420 | 1.00 | CHRNA7 (1.00) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| Pnu-282987 SCHEMBL10436185 | 1.00 | CHRNA7 (1.00) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| Pnu-282987 SCHEMBL9601902 | 0.99 | CHRNA7 (0.97) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| Pnu-282987 SCHEMBL1118980 | 0.99 | CHRNA7 (0.97) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| Pnu-282987 SCHEMBL7281159 | 0.99 | CHRNA7 (0.97) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6209105 | 0.93 | CHRNA7 (0.86) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| Pnu-282987 SCHEMBL5598576 | 0.92 | CHRNA7 (0.85) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| Pnu-282987 SCHEMBL5598573 | 0.92 | CHRNA7 (0.85) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL373483 | 0.92 | CHRNA7 (0.85) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL372855 | 0.92 | CHRNA7 (0.85) | CHRNA7HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-11-02 | — | — | US | claimed |
| US-20220117989-A1 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-04-21 | — | — | US | claimed |
| US-20210145818-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | Poviva Corp. | 2021-05-20 | — | — | US | claimed |
| EP-3781163-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | Poviva Corp. (US) | 2021-02-24 | — | — | EP | claimed |
| EP-3284467-B1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA INC (US) | 2019-10-30 | — | — | EP | claimed |
| WO-2019202396-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | POVIVA TEA, LLC (US) | 2019-10-24 | — | — | WO | claimed |
| EP-3284467-A1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | Niconovum USA, Inc. (US) | 2018-02-21 | — | — | EP | claimed |
| EP-2566476-B1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA INC (US) | 2017-11-22 | — | — | EP | claimed |
| US-20170326138-A1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA, INC. (US) | 2017-11-16 | — | — | US | claimed |
| US-20170273957-A1 | ANTITUSSIVE COMPOSITIONS AND METHODS | ATTENUA, INC. | 2017-09-28 | — | — | US | claimed |
| EP-1863485-A2 | ALPHA7 NEURONAL NICOTINIC RECEPTOR LIGAND AND ANTIPSYCHOTIC COMPOSITIONS | ABBOTT LABORATORIES (US) | 2007-12-12 | — | — | EP | claimed |
| WO-2006101745-A2 | ALPHA7 NEURONAL NICOTINIC RECEPTOR LIGAND AND ANTIPSYCHOTIC COMPOSITIONS | ABBOTT LABORATORIES (US) | 2006-09-28 | — | — | WO | claimed |
| US-20060211686-A1 | Alpha7 Neuronal nicotinic receptor ligand and antipsychotic compositions | ABBOTT LABORATORIES | 2006-09-21 | — | — | US | claimed |
| US-20060019984-A1 | Treatment of diseases with alpha-7nACh receptor full agonists | PFIZER INC | 2006-01-26 | — | — | US | claimed |
| US-20050245504-A1 | Treatment of diseases with combinations of alpha 7 Nicotinic Acetylcholine Receptor agonists and other compounds | CORBETT JEFFREY W | 2005-11-03 | — | — | US | claimed |
| EP-1572205-A2 | TREATMENT OF DISEASES WITH COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS AND OTHER COMPOUNDS | Pharmacia & Upjohn Company LLC (US) | 2005-09-14 | — | — | EP | claimed |
| EP-1572300-A1 | COMBINATION FOR THE TREATMENT OF ADHD | Pharmacia & Upjohn Company LLC (US) | 2005-09-14 | — | — | EP | claimed |
| US-20050107425-A1 | Treatment of attention defecit hyperactivity disorder | PFIZER INC | 2005-05-19 | — | — | US | claimed |
| WO-2004052461-A1 | COMBINATION FOR THE TREATMENT OF ADHD | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | claimed |
| WO-2004052348-A2 | TREATMENT OF DISEASES WITH COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS AND OTHER COMPOUNDS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | RAB5IF, CLTB, TBK1 | CHRNA7 4663/4885HTR3E 4324/4885HTR3B 4317/4885 |
| US-20050245504-A1 | Treatment of diseases with combinations of alpha 7 Nicotinic Acetylcholine Receptor agonists and other compounds | CHRNA7, CHRNG, CHRNE | CHRNA7 1/4885HTR3E 673/4885HTR3B 326/4885 |
| US-20170273957-A1 | ANTITUSSIVE COMPOSITIONS AND METHODS | CHRNA7, CHRNA1, CHRNG | CHRNA7 1/4885HTR3E 235/4885HTR3B 93/4885 |
| US-20060019984-A1 | Treatment of diseases with alpha-7nACh receptor full agonists | CHRNA7, CHRNA1, CHRNG | CHRNA7 1/4885HTR3E 837/4885HTR3B 334/4885 |
| US-20060211686-A1 | Alpha7 Neuronal nicotinic receptor ligand and antipsychotic compositions | CHRNA7, CHRNA5, CHRNA6 | CHRNA7 1/4885HTR3E 182/4885HTR3B 87/4885 |
| US-20210145818-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | CHRNA5, SLC18A3, CHRNA6 | CHRNA7 12/4885HTR3E 320/4885HTR3B 232/4885 |
| US-20220117989-A1 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | EYA3, RB1, ALDH1A2 | CHRNA7 323/4885HTR3E 1566/4885HTR3B 2296/4885 |
| US-20050107425-A1 | Treatment of attention defecit hyperactivity disorder | CHRNA7, CHRNA10, SLC18A3 | CHRNA7 1/4885HTR3E 45/4885HTR3B 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.